Essentra (LON:ESNT – Get Free Report) had its price target lowered by stock analysts at Berenberg Bank from GBX 255 ($3.41) to GBX 200 ($2.68) in a research note issued to investors on Tuesday, Digital Look reports. The firm presently has a “buy” rating on the stock. Berenberg Bank’s price objective indicates a potential upside of 32.80% from the company’s previous close.
Other analysts have also recently issued research reports about the stock. Jefferies Financial Group lowered their price objective on shares of Essentra from GBX 260 ($3.48) to GBX 250 ($3.35) and set a “buy” rating for the company in a research report on Friday, July 12th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Essentra from GBX 240 ($3.21) to GBX 200 ($2.68) and set a “buy” rating for the company in a research report on Tuesday, September 17th.
Get Our Latest Analysis on Essentra
Essentra Trading Up 1.8 %
Insider Activity at Essentra
In related news, insider Scott Fawcett purchased 10,479 shares of Essentra stock in a transaction that occurred on Wednesday, September 18th. The stock was purchased at an average cost of GBX 142 ($1.90) per share, with a total value of £14,880.18 ($19,925.25). Insiders own 0.93% of the company’s stock.
About Essentra
Essentra plc manufactures and distributes plastic injection and vinyl dip moulded, and metal components worldwide. The company offers cable ties and conduit, and accessories; grommets, strain relief, and blanking plugs; cable glands and accessories; caps and plugs; card guides and pullers; circuit board hardware products; EMI suppression ferrite cores; fan accessories comprising filters and fan mounting accessories; screws and nuts; rivet and panel fasteners; barbed and push-fit fasteners; binder screws and snap fasteners; washers; spacers; brushes; feet; fibre management; and furniture fittings.
Read More
- Five stocks we like better than Essentra
- How to Effectively Use the MarketBeat Ratings Screener
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Health Care Stocks Explained: Why You Might Want to Invest
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- 3 Tickers Leading a Meme Stock Revival
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Essentra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Essentra and related companies with MarketBeat.com's FREE daily email newsletter.